FDA Commissioner's Status Unclear Amid Reported Push for Removal
Similar Articles
FDA Commissioner Marty Makary Resigns After 13-Month Tenor
FDA Commissioner Marty Makary Removed After Pressure Over Vape Approvals
FDA Acting Drug Center Director Tracy Beth Hoeg Removed
HHS Confirms FDA Blocked Publication of Vaccine Studies
Trump Administration Appeals Injunction Against CDC Vaccine Policy Changes
The status of Food and Drug Administration (FDA) Commissioner Marty Makary is uncertain following reports of a push for his removal. President Trump has stated he knows nothing about the reports, while a White House official indicated senior Health and Human Services leaders were behind the possible firing. Makary is scheduled to testify before a Senate committee this week.
Facts First
- FDA Commissioner Marty Makary's status is uncertain amid reports senior HHS leaders are pushing for his removal.
- President Trump said he knows nothing about the reported firing when asked directly about it.
- Makary is scheduled to testify on the FDA's 2027 budget at a Senate hearing this Wednesday.
- The agency faces key staffing vacancies and has seen significant decreases in staff at key centers since 2021.
- High-profile decisions on treatments for cancer and rare diseases are pending at the agency.
What Happened
Multiple outlets reported last week that President Trump had authorized the firing of FDA Commissioner Marty Makary. When asked about these reports on Friday, President Trump replied, 'I've been reading about it, but I know nothing about it.' A White House official told Politico that senior Health and Human Services (HHS) leaders were pushing for the possible firing. The White House did not respond to other questions regarding Makary's status.
Why this Matters to You
The FDA regulates approximately one-fifth of the U.S. economy, including the safety of food, drugs, and medical treatments. Uncertainty in its leadership could affect the agency's ability to make timely decisions on new medicines. This may impact your access to experimental treatments for conditions like cancer, ADHD, and rare diseases, which are currently pending review. The agency's staffing challenges might also slow down the approval process for new products.
What's Next
Commissioner Makary is scheduled to testify on the FDA's 2027 budget at a Senate Appropriations Committee hearing on Wednesday. His appearance may provide clarity on his standing and the agency's direction. If Makary were to depart, potential candidates to run the agency could include internal candidate Kyle Diamantas, the deputy commissioner for food, or former officials like Stephen Hahn and Brett Giroir. The agency's plan to hire an additional 3,000 scientists may be a key topic in upcoming discussions about its capacity.